These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3001 related articles for article (PubMed ID: 32249203)

  • 21. A systematic review of SARS-CoV-2 vaccine candidates.
    Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
    Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice.
    Li E; Yan F; Huang P; Chi H; Xu S; Li G; Liu C; Feng N; Wang H; Zhao Y; Yang S; Xia X
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31968702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
    Qi X; Ke B; Feng Q; Yang D; Lian Q; Li Z; Lu L; Ke C; Liu Z; Liao G
    Chem Commun (Camb); 2020 Aug; 56(61):8683-8686. PubMed ID: 32613971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
    Coleman CM; Venkataraman T; Liu YV; Glenn GM; Smith GE; Flyer DC; Frieman MB
    Vaccine; 2017 Mar; 35(12):1586-1589. PubMed ID: 28237499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.
    Li K; Li Z; Wohlford-Lenane C; Meyerholz DK; Channappanavar R; An D; Perlman S; McCray PB; He B
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice.
    Li E; Chi H; Huang P; Yan F; Zhang Y; Liu C; Wang Z; Li G; Zhang S; Mo R; Jin H; Wang H; Feng N; Wang J; Bi Y; Wang T; Sun W; Gao Y; Zhao Y; Yang S; Xia X
    Viruses; 2019 Aug; 11(9):. PubMed ID: 31470645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
    Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
    J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Chen WH; Tao X; Agrawal AS; Algaissi A; Peng BH; Pollet J; Strych U; Bottazzi ME; Hotez PJ; Lustigman S; Du L; Jiang S; Tseng CK
    Vaccine; 2020 Nov; 38(47):7533-7541. PubMed ID: 33039209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
    Wang Y; Tai W; Yang J; Zhao G; Sun S; Tseng CK; Jiang S; Zhou Y; Du L; Gao J
    Hum Vaccin Immunother; 2017 Jul; 13(7):1615-1624. PubMed ID: 28277821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of candidate vaccine approaches for MERS-CoV.
    Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
    Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Zhang C; Zhou C; Shi L; Liu G
    Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
    Tai W; Zhao G; Sun S; Guo Y; Wang Y; Tao X; Tseng CK; Li F; Jiang S; Du L; Zhou Y
    Virology; 2016 Dec; 499():375-382. PubMed ID: 27750111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen.
    Ahuja R; Vishwakarma P; Raj S; Kumar V; Khatri R; Lohiya B; Saxena S; Kaur G; Singh G; Asthana S; Ahmed S; Samal S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2351664. PubMed ID: 38757508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.
    Choi J; Kim MG; Oh YK; Kim YB
    Expert Opin Ther Pat; 2017 Jun; 27(6):721-731. PubMed ID: 28121202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity.
    Kim J; Yang YL; Jang SH; Jang YS
    Virol J; 2018 Aug; 15(1):124. PubMed ID: 30089512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stabilized coronavirus spike stem elicits a broadly protective antibody.
    Hsieh CL; Werner AP; Leist SR; Stevens LJ; Falconer E; Goldsmith JA; Chou CW; Abiona OM; West A; Westendorf K; Muthuraman K; Fritch EJ; Dinnon KH; Schäfer A; Denison MR; Chappell JD; Baric RS; Graham BS; Corbett KS; McLellan JS
    Cell Rep; 2021 Nov; 37(5):109929. PubMed ID: 34710354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospects for a MERS-CoV spike vaccine.
    Zhou Y; Jiang S; Du L
    Expert Rev Vaccines; 2018 Aug; 17(8):677-686. PubMed ID: 30058403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.
    Kim E; Weisel FJ; Balmert SC; Khan MS; Huang S; Erdos G; Kenniston TW; Carey CD; Joachim SM; Conter LJ; Weisel NM; Okba NMA; Haagmans BL; Percivalle E; Cassaniti I; Baldanti F; Korkmaz E; Shlomchik MJ; Falo LD; Gambotto A
    Eur J Immunol; 2021 Jul; 51(7):1774-1784. PubMed ID: 33772778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 151.